Effect of low-dose sacubitril/valsartan on body composition, bioelectrical impedance analysis, heart rate variability and T-peak to T-end index in elderly patients with severe chronic heart failure: a pilot experience

Marchitto, Nicola; Sindona, Francesco; Mobilia, Pasquale; Dalmaso, S; Raimondi, Gianfranco

doi:10.1080/03007995.2019.1576484

Cited by 5 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty‐one articles, 10 retrospective and 11 prospective, were selected 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 (Supporting Information, Figure S1 and Tables S2 and S3 ). Collectively, these studies included 16 952 patients: 12 082 (71.3%) were accounted for by a single article, 16 while the sample size of the other ones varied from 11 (0.06%) to 2037 (12.0%) subjects.…”

Section: Resultsmentioning

confidence: 99%

“…Collectively, these studies included 16 952 patients: 12 082 (71.3%) were accounted for by a single article, 16 while the sample size of the other ones varied from 11 (0.06%) to 2037 (12.0%) subjects. 11 , 12 , 13 , 14 , 15 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 Four investigations included patients in NYHA class I (Lopez‐Azor 23 : 1.1%; Vicent 18 : 1.2%; Kakuzna 11 : 3.0%; and Pharithi 24 : 10.4%).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Sacubitril/valsartan in real‐life European patients with heart failure and reduced ejection fraction: a systematic review and meta‐analysis

et al. 2021

View full text Add to dashboard Cite

AimsWe systematically reviewed the European real-world evidence (RWE) about sacubitril-valsartan for heart failure with reduced ejection fraction. Methods and results Twenty-one articles, including 16 952 subjects, were identified until 31 October 2020. Taking as reference the PARADIGM-HF cohort, few baseline characteristics were presented in >80% of these studies, most often with high heterogeneity. In random-effects model meta-analysis, age was higher (mean difference +3.84, 95% CI 1.92-5.76), ischaemic aetiology (OR 0.76, 95% CI 0.64-0.91), hypertension (OR 0.55, 95% CI 0.37-0.82), and diabetes (OR 0.77, 95% CI 0.64-0.92) were less common, and the use of mineralocorticoid receptor antagonists was more frequent (OR 3.54, 95% CI 2.27-5.53) in real-life than in PARADIGM-HF. Other clinical and medical features were presented in 19-76% of the selected publications and suggested more severe heart failure with reduced ejection fraction. Sacubitril-valsartan was titrated to 97/103 mg b.i.d. in 35% (95% CI 23-47) and discontinued in 12.8% (95% CI 7.4-18.3) patients. When reported, the incidence of hyperkalaemia (six studies, no. 1076), all-cause mortality (five studies, no. 684), and any hospitalization (three studies, no. 390) was 12 (95% CI 5-19)/100 person-year, 8 (95% CI 4-12)/100 person-year, and 24 (95% CI 5-42)/100 person-year, respectively. Knowledge contribution, a metric measuring the proportion of RWE provided by each article based on the number of reported variables and the sample size, was 58.8% and 13.6% for the two biggest investigations (12 082 and 2037 patients), and <5% for all others (most with <100 subjects). Conclusions Limited-quality RWE indicates that there are important differences between European patients prescribed sacubitril-valsartan and the PARADIGM-HF population, including the frequency of target dose achievement.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Sacubitril/valsartan in real‐life European patients with heart failure and reduced ejection fraction: a systematic review and meta‐analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Heart rate variability (HRV) has been studied extensively in patients with normal sinus rhythm and shown to have important prognostic implications for various cardiovascular disorders like coronary artery disease, congestive heart failure, hypertension, and so on 9‐11 . It analyses variation in the beat‐to‐beat intervals of the heart and reflects the parasympathetic nervous system (PNS) and the sympathetic nervous system (SNS) balance 12 .…”

Section: Introductionmentioning

confidence: 99%

The predictive value of heart rate variability indices tested in early period after radiofrequency catheter ablation for the recurrence of atrial fibrillation

Zhu

Wang

Cheng

et al. 2020

Cardiovasc electrophysiol

View full text Add to dashboard Cite

Introduction: To explore the relationship between recurrence of atrial fibrillation (AF) and the autonomic nervous activity evaluated by heart rate variability (HRV) indices after radiofrequency catheter ablation (RFCA) in the early period. Methods:We enrolled 102 patients with paroxysmal AF and tested the HRV indices by the high-resolution Holter electrocardiogram the next morning after RFCA. The HRV indices were compared between the non-recurrence group (n = 85) and the recurrence group (n = 17). Results:The HRV indices included standard deviation of normal to normal intervals (SDNN), SDNN index, root-mean square successive differences (RMSSD), the proportion of normal to normal intervals differing by >50 millisecond (ms) (pNN50), high-frequency components (HF), low-frequency components (LF) and very lowfrequency components were significantly higher in recurrence group than that in non-recurrence group, while no such difference was found for LF/HF. Based on the median value of the recurrent time (9 months), RMSSD (P = .012), pNN50 (P < .0001) and HF (P = .033) were lower in late recurrence group than that in early recurrence group. The Cox regression analyses indicated that higher values of RMSSD (P = .01), pNN50 (P = .02) and HF (P = .02) were associated with a higher risk of recurrence after adjusted for covariates. The receiver operating characteristic curves showed higher rates of clinical recurrence of AF after RFCA in patients with RMSSD ≥27.5 ms, pNN50 ≥4.5%, and HF ≥178.25 ms 2 .Conclusions: Values of RMSSD, pNN50, and HF tested in the early period after RFCA could independently predict the recurrence of AF. K E Y W O R D S atrial fibrillation, autonomic nervous activity, heart rate variability, radiofrequency catheter ablation, recurrence

show abstract

Angiotensin Receptor Neprilysin Inhibitors—2019 Update

Chalikias

Tziakas

2020

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

Effect of low-dose sacubitril/valsartan on body composition, bioelectrical impedance analysis, heart rate variability and T-peak to T-end index in elderly patients with severe chronic heart failure: a pilot experience

Cited by 5 publications

References 3 publications

Sacubitril/valsartan in real‐life European patients with heart failure and reduced ejection fraction: a systematic review and meta‐analysis

Sacubitril/valsartan in real‐life European patients with heart failure and reduced ejection fraction: a systematic review and meta‐analysis

The predictive value of heart rate variability indices tested in early period after radiofrequency catheter ablation for the recurrence of atrial fibrillation

Angiotensin Receptor Neprilysin Inhibitors—2019 Update

Contact Info

Product

Resources

About